U.S. markets closed

Adverum Biotechnologies, Inc. (ADVM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.6408-0.0191 (-2.89%)
At close: 04:00PM EST
0.6545 +0.01 (+2.14%)
After hours: 05:46PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close0.6599
Bid0.6403 x 1800
Ask0.6545 x 800
Day's Range0.6400 - 0.6700
52 Week Range0.6300 - 2.0400
Avg. Volume506,961
Market Cap63.906M
Beta (5Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-1.5780
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ADVM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adverum Biotechnologies, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/25/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    7 months agoArgus Research
View more
  • GlobeNewswire

    Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee. On December 1, 2022, Adverum granted a new employee a stock option to purchase 200,000 shares of Adverum’s common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is m

  • GlobeNewswire

    Adverum Biotechnologies Reports Third Quarter 2022 Financial Results

    - First subject dosed in our Phase 2 LUNA trial with Ixo-vec (ixoberogene soroparvovec, formerly referred to as ADVM-022) and anticipate preliminary data throughout 2023 - Cash runway into 2025 prioritizing Ixo-vec clinical development in wet age-related macular degeneration (wet AMD) REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocul

  • GlobeNewswire

    Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)

    - Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in participants in the OPTIC extension study - 81% – 98% reduction in mean annualized anti-VEGF injections after a single IVT injection of Ixo-vec, including 80% and 53% of participants supplemental injection free over two years across the 6x10^11 (6E11) and 2x10^11 (2E11) doses, respectively, regardless of